论文部分内容阅读
目的观察沙格雷酯治疗糖尿病下肢血管病变的效果。方法 40例患者按1:1随机进入沙格雷酯组(20例)和西洛他唑组(20例)。沙格雷酯用量为300mg/d,西洛他唑100mg/d,共两个月。比较两组治疗前后及其组间下肢血管病变、神经病变的症状、无痛行走距离、能耐受疼痛的最大行走距离和踝/肱血压指数(ABI)。结果沙格雷酯组主观症状明显改善,最大行走和无痛行走距离、ABI及足背动脉血管流速均显著增加。结论沙格雷酯对糖尿病下肢血管病变是一种安全有效的药物。
Objective To observe the effect of sarpogrelate on diabetic lower limb vascular disease. Methods Forty patients were randomized into the sagereptomy group (n = 20) and the cilostazol group (n = 20) by 1: 1. Sagrast ester dosage of 300mg / d, cilostazol 100mg / d, a total of two months. The severity of lower extremity vascular lesions, neurological symptoms, painless walking distance, pain-tolerant maximum walking distance and ankle / brachial blood pressure index (ABI) were compared between the two groups before and after treatment. Results The subjective symptom of sarpogrelate group was significantly improved. The maximum distance of walking and painless walking, blood flow velocity of ABI and dorsalis pedis artery were all significantly increased. Conclusion Saregrag is a safe and effective drug for diabetic lower extremity vascular disease.